MGI Tech launches VisiOmics AI pathology system in Europe

MGI Tech Co., Ltd. said VisiOmics (PMIF-20RS) — a fully automated multiplex immunofluorescence staining and imaging system with AI-powered analysis via FluoXpert Vision — is now commercially available in Europe. The launch was announced at the 38th European Congress of Pathology (ECP 2026) in Stockholm as part of a broader “From Tissue to Answer” pathology portfolio.

HEALTH desk — same-day primary European commercial launch of an AI-enabled pathology imaging system, expanding automated spatial-proteomics tools labs can buy now.

Availability, as the same wire has it: VisiOmics is now commercially available in Europe. The company says the system enables multiplex detection of protein markers in a single tissue section and walk-away automation of the full staining-to-imaging workflow. Walk-away here means the lab can load the run and leave the machine to stain and image without standing over each step. File Europe-now-for-sale and that walk-away picture as MGI’s. This desk did not watch a lab install and is not inventing U.S. availability, an FDA clearance, a price, or a hospital deployment count. None of those are on this page.

Stated specs, still company: more than 20-plex detection per run, expandable to more than 100 markers from a single tissue section via cyclic staining. Plex is how many protein markers the system reads in one run. Cyclic staining means repeating stain-and-image cycles to add more markers on the same slice. AI-powered image analysis is branded FluoXpert Vision and includes cell segmentation, phenotyping, and spatial analysis, plus a dedicated AI assistant the company says lowers the barrier for downstream analysis and data visualization. Segmentation means drawing each cell in the image. Phenotyping means classifying cell types from that image. Spatial analysis means mapping where those cell types sit relative to each other in the tissue. File those plex numbers and that FluoXpert Vision job as MGI’s. This desk did not count markers or score a slide.

Portfolio context, as the same announcement frames it under the theme “From Tissue to Answer”: MGI is also showcasing Path-P96 WF, a customisable high-throughput multiplex immunofluorescence platform using standard pathology slides. The company says that system processes up to 32 slides per batch, supports continuous loading and walk-away operation, and can detect more than 100 protein markers through cyclic staining, including work in drug discovery and spatial biology. On the molecular-pathology side, MGI is presenting PrepLPS (PrepALL Library Prep Edition), a compact liquid-handling platform for next-generation sequencing library preparation with eight independent channels (0.5–1,200 µL), AI-based machine vision, and ready-to-run workflows — Early Access is now open for European laboratories — and AIO (All-in-one), a sample-to-result sequencing platform the company says condenses library preparation, sequencing, and reporting into about 11 hours with roughly 10 minutes of hands-on time. AIO is demonstrated live at the booth and is open for OEM partnerships in Europe. OEM here means another company can put its own name or workflow on the box. File Path-P96 WF, PrepLPS Early Access, and AIO’s 11-hour / 10-minute / OEM lines as MGI’s. This desk did not time a sequencing run.

Partnership demo, still company: MGI is partnering with the Fraunhofer Institute for Integrated Circuits IIS to show that multiplex immunofluorescence images from VisiOmics can be used in MIKAIA, Fraunhofer IIS’s image-analysis software for digital pathology and spatial biology. The company says the aim is cell segmentation, phenotyping, and spatial analysis inside MIKAIA workflows. File that compatibility demo as MGI’s. This desk did not run MIKAIA.

AI across the portfolio, as the same wire attributes it: backed by Genoria AI, an MGI subsidiary. Each platform is described as shipping with AI-powered image analysis (FluoXpert Vision on PMIF-20RS), natural-language workflow orchestration on Path-P96 WF, machine-vision monitoring on PrepALL, and intelligent library-pooling strategies on AIO. File that Genoria-backed stack as MGI’s. This desk did not audit the subsidiary’s models.

Named voice on the release: Fang Chen, Vice President of MGI and General Manager of Europe & Africa. He talks about pathology research combining morphological assessment — looking at tissue under the microscope — with multiplex spatial proteomics, meaning many proteins mapped in place on a tissue slice, and about offering a complete “From Tissue to Answer” portfolio whether the starting point is proteins in tissue or nucleic acids in a sample. File the name and title as his, via MGI. His quotes are color only and stay in Sources.

About box, still company: MGI was founded in 2016. Stock code 688114.SH. The company says it develops core tools for life science, including clinical-grade gene sequencers and a portfolio spanning sequencing, lab intelligence, and multi-omics — reading more than one class of biological molecule, such as DNA and proteins, from the same research program. File the 2016 founding, the ticker, and that product-family line as MGI’s. This is not a stock tip.

Plain English for the rest of the card: multiplex immunofluorescence (mIF) = staining many protein markers on one tissue slice. plex = how many markers in a run. cyclic staining = repeating stain-and-image cycles to add more markers on the same slice. phenotyping = classifying cell types from the image. spatial proteomics = mapping many proteins in place in tissue. ECP = European Congress of Pathology, the European pathology meeting. walk-away automation = load the run and leave the machine to stain and image. OEM = another company putting its name or workflow on the box.

PRIMARY here: MGI Tech’s 15 Sep 2026 PR Newswire company release — Tier A PRIMARY company source, the original record. The company English-language site is product-home context, not a second originating newsroom. The European VisiOmics (PMIF-20RS) launch, Europe commercial availability, walk-away staining-to-imaging automation, the more-than-20-plex / more-than-100-marker cyclic-staining specs, FluoXpert Vision cell segmentation / phenotyping / spatial analysis plus AI assistant, the Path-P96 WF showcase, PrepLPS Early Access for European labs, AIO’s about-11-hour / roughly-10-minute-hands-on sample-to-result line and European OEM opening, the Fraunhofer IIS MIKAIA compatibility demo, Genoria AI as the MGI subsidiary behind portfolio AI, the Fang Chen title, and the 2016 founding / 688114.SH about-box are company-attributed. Product specs, availability, and partnership language stay company-attributed — not independently measured here. NOT claimed: U.S. FDA clearance, U.S. commercial availability, a price list, hospital or lab deployment counts, clinical-trial endpoints, that this desk ran VisiOmics or sat at ECP, a stock tip, or investment advice. Distinct from the already-filed latent-health-60-systems, aitiologic-6-4m-seed, insilico-longevity-vaccines, openevidence-penn-medicine, microstructure-imaging-micsi-pet-fda, sonus-medtronic-maternal-ultrasound-ai, openai-foundation-public-data-health, unc-openai-foundation-40m-cancer-vaccines, azmed-azchest-fda-6th, and powerful-medical-queen-of-hearts-fda-de-novo.